FDA Approves AstraZeneca COPD Medicine
AstraZeneca announced that the FDA has approved its SYMBICORT (budesonide/formoterol fumarate dihydrate) inhalation aerosol 160/4.5 micrograms to decrease exacerbations of chronic obstructive pulmonary disease (COPD).
SYMBICORT 160/4.5 works to maintain treatment of airflow obstruction in patients with COPD-including chronic bronchitis and/or emphysema-and to lessen COPD exacerbations.
SYMBICORT has not been indicated for the relief of acute bronchospasm.
For mor information, read the prescribing information, boxed warning, and medication guide here.
FDA Approves AbbVie’s Rinvoq as First Oral JAK Inhibitor for Giant Cell Arteritis
April 30th 2025AbbVie secures FDA approval for Rinvoq as the first oral Janus kinase inhibitor indicated for giant cell arteritis, expanding its immunology portfolio and signaling strategic growth opportunities in underserved autoimmune markets.
Navigating Distrust: Pharma in the Age of Social Media
February 18th 2025Ian Baer, Founder and CEO of Sooth, discusses how the growing distrust in social media will impact industry marketing strategies and the relationships between pharmaceutical companies and the patients they aim to serve. He also explains dark social, how to combat misinformation, closing the trust gap, and more.
